Clinical Trials Sponsored by Dey LP

Total 27955 results

Purdue Pharma LP

Completed

Safety and Efficacy of Buprenorphine Transdermal System in Subjects With Moderate to Severe Osteoarthritis of Hip or Knee

Osteoarthritis

United States
Purdue Pharma LP

Completed

To Determine the Fed Bioequivalence of Reformulated OXY Tablets and Original OxyContin® (OXY) Tablets

Healthy

United States
Purdue Pharma LP

Completed

A Study to Determine the Fasting Bioequivalence of Reformulated OXY Tablets and Original OxyContin® (OXY) Tablets

Healthy

United States
Purdue Pharma LP

Completed

A Study to Determine the Fed Bioequivalence of Reformulated OXY Tablets and Original OxyContin® (OXY) Tablets

Healthy Volunteers

United States
Purdue Pharma LP

Terminated

Efficacy and Safety of Hydromorphone Hydrochloride Extended-Release Compared to Placebo in Subjects With Persistent Pain

Chronic Non-Malignant Pain

United States
Purdue Pharma LP

Completed

Safety and Efficacy of the Buprenorphine Transdermal Delivery System in Subjects With Osteoarthritis Pain.

Osteoarthritis

United States
Bayer
Janssen, LP

Completed

Study to Gather Information About the Safety of Oral Anticoagulation Drugs and How Well These Drugs Work in Real World for Patients With Non-valvular Atrial Fibrillation (Irregularly Heart Beats Which is Not Caused by a Heart Valve Problem) (REATTAIN)

Atrial Fibrillation

Sweden
Purdue Pharma LP

Terminated

Real-World Evidence of Duration of Effect of Adhansia XR (Extended-Release) for Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) (RE-DAX)

Attention-Deficit/Hyperactivity Disorder

United States
Ridgeback Biotherapeutics, LP

Completed

COVID-19 First In Human Study to Evaluate Safety, Tolerability, and Pharmacokinetics of EIDD-2801 in Healthy Volunteers

Coronavirus

United Kingdom
Purdue Pharma LP

Completed

Long-term Safety of Once-daily Hydrocodone Bitartrate (HYD) Tablets For Moderate to Severe Chronic Nonmalignant and Nonneuropathic Pain. Includes a 24-week Extension Period.

Chronic Nonmalignant and Nonneuropathic Pain

United States
Purdue Pharma LP

Completed

Efficacy and Safety of Hydrocodone Bitartrate (HYD) in Subjects With Moderate to Severe Chronic Low Back Pain

Chronic Low Back Pain

United States
Purdue Pharma LP

Withdrawn

Safety, Pharmacokinetics (PK), and Effectiveness of Hydrocodone Bitartrate (HYD) Extended-Release Tablets in Children

Pain
Purdue Pharma LP

Completed

To Determine the Fasting Bioequivalence of Reformulated OXY Tablets Manufactured at Two Different Facilities

Healthy

United States
Purdue Pharma LP

Completed

Long-Term Safety of Twice Daily Oxycodone Hydrochloride Controlled-release Tablets in Children Who Completed OTR3001

Pain

United States, Israel
Purdue Pharma LP

Completed

Analgesic Efficacy and Management of Opioid-induced Constipation (OIC) for Uncontrolled Moderate - Severe Low Back Pain

Low Back Pain

United States, Poland, Czech Republic, Italy
Purdue Pharma LP

Completed

Buprenorphine Accumulation and Description of Its Metabolites During Co-Medication of Buprenorphine Transdermal System (BTDS) and Ketoconazole

Healthy

United States
Purdue Pharma LP

Completed

Analgesic Efficacy and Safety of V116517 in Subjects With Moderate to Severe Chronic Pain Due to Postherpetic Neuralgia (PHN)

Pain | Postherpetic Neuralgia

United States
Purdue Pharma LP

Completed

Pharmacokinetics and Safety of ORF Tablets in Pediatric Patients

Opioid Analgesia

United States, Australia, Finland, New Zealand
Purdue Pharma LP

Terminated

Safety of Buprenorphine Transdermal Patch (BTDS) in Osteoarthritis Pain: a 52-Week Extension Phase

Osteoarthritis

United States
Purdue Pharma LP

Terminated

Safety of BTDS in Subjects With Low Back Pain: A 52-Week Extension Phase of BUP3015

Back Pain Lower Back Chronic

United States
Purdue Pharma LP

Terminated

Buprenorphine Transdermal Patch in Subjects With Osteoarthritis Pain Requiring Opioids. Includes a 52-Week Safety Extension.

Osteoarthritis

United States
Purdue Pharma LP

Completed

Safety and Efficacy of Dose Conversion From Vicodin® to Buprenorphine Transdermal System (Butrans™) in Subjects With OA Pain

Osteoarthritis

United States
Purdue Pharma LP

Completed

A Study to Determine the Fasting Bioequivalence of Reformulated OXY Tablets Manufactured at Two Different Facilities

Healthy

United States
Purdue Pharma LP

Completed

A Study to Determine the Fed Bioequivalence of Reformulated OXY Tablets and Original OxyContin® (OXY) Tablets

Healthy Volunteers

United States
Purdue Pharma LP

Completed

The Safety and Efficacy of the Buprenorphine Transdermal Delivery System in Subjects With Osteoarthritis Pain.

Osteoarthritis

United States
Purdue Pharma LP

Completed

The Safety and Efficacy of the Buprenorphine Transdermal Delivery System in Subjects With Chronic Back Pain.

Chronic Low Back Pain

United States
Purdue Pharma LP

Completed

Safety and Effectiveness of Buprenorphine Transdermal System in Elderly Subjects With Chronic Pain: Pilot Study.

Chronic Pain

United States
Purdue Pharma LP

Completed

Safety of the Buprenorphine Transdermal Delivery System in Subjects With Mod-to-Sev Pain Following Orthopedic Surgery.

Postoperative Pain

United States
Hospices Civils de Lyon
Janssen, LP

Completed

Multiple Myeloma Minimal Residual Disease (MMRD)

Multiple Myeloma

France
ViiV Healthcare
Janssen, LP

Completed

A Study to Evaluate Efficacy and Safety of Cabotegravir (CAB) Long Acting (LA) Plus (+) Rilpivirine (RPV) LA Versus BIKTARVY® (BIK) in Participants With Human Immunodeficiency Virus (HIV)-1 Who Are Virologically Suppressed (SOLAR)

HIV Infections

United States, Netherlands, Germany, Canada, Australia, Belgium, France, Spain, Ireland, Italy, United Kingdom, Austria, Japan, Switzerland
Pfizer
OxOnc Development LP

Completed

Phase II Safety and Efficacy Study of Crizotinib in East Asian Patients With ROS1 Positive, ALK Negative Advanced NSCLC

Non Small Cell Lung Cancer | Crizotinib | ROS1 Proto Oncogene

Korea, Republic of, China, Taiwan, Japan
Reproductive Research Technologies, LP

Completed

Comparison of SureCALL® EMG Labor Monitor® and Tocodynamometer to Intrauterine Pressure Catheter Measurement (IUPC) Measurement in Pregnant Women

Pregnancy - Labor Monitoring

United States
Georgetown University
Janssen, LP

Recruiting

Daratumumab for Polyneuropathy Associated With MGUS (Dara-MGUS)

Monoclonal Gammopathy of Undetermined Significance | Peripheral Neuropathy

United States
ViiV Healthcare
Janssen, LP

Completed

Study to Evaluate Pharmacokinetics, Safety and Tolerability of Dolutegravir and Rilpivirine (JULUCA™) 50 Milligram (mg)/25 mg Tablets in Healthy Subjects of Japanese Descent

HIV Infections

United States
MED-LIFE DISCOVERIES LP

Unknown

RCDP Natural History Study

Rhizomelic Chondrodysplasia Punctata

United States
Purdue Pharma LP
Shionogi

Completed

A Study to Evaluate the Analgesic Efficacy and Safety of V120083 in Subjects With Osteoarthritis (OA) of the Knee

Osteo Arthritis Knee

United States
Duke University
Janssen, LP

Completed

Obesity in HIV After Antiretroviral Therapy

Obesity | HIV | AIDS

United States
Emory University
Janssen, LP

Completed

Civilian Post-Traumatic Stress Disorder Risperidone Clinical Trial

Post-Traumatic Stress Disorders

United States
Duke University
Janssen, LP

Completed

Determining the Effects of Risperdal Consta in Patients With Psychotic Disorders and Incomplete Adherence

Schizophrenia | Schizoaffective Disorder

United States
Reproductive Research Technologies, LP

Completed

Comparison of SureCALL® Labor Monitor® and Tocodynamometer Measurement in Preterm and Term Pregnant Women

Pregnancy

United States
Reproductive Research Technologies, LP

Completed

Multi-Reader Multi-Case Study to Identify Uterine Contractions Recorded From Laboring and Nonlaboring Patients by Practicing Clinicians

Pregnancy

United States
Reproductive Research Technologies, LP

Completed

Multi-Reader Multi-Case Study to Identify Uterine Contractions Recorded From Laboring Patients by Practicing Clinicians

Pregnancy - Labor Monitoring

United States
Assistance Publique - Hôpitaux de Paris
Janssen, LP

Completed

Study of Dose Escalation of Abiraterone Actetate in Prostate Cancer (OPTIMABI)

Prostate Cancer

France
ViiV Healthcare
Janssen, LP

Completed

Phase 2b, Open-label, Multicenter, Rollover Study to Assess Antiviral Activity and Safety of Long-acting (LA) Cabotegravir (CAB) Plus LA Rilpivirine (RPV), Administered Every 2 Months (Q2M), in Human Immunodeficiency Virus (HIV)-Positive Participants From the LATTE Study

HIV Infections

United States, Canada
Pharmacyclics LLC.
Janssen, LP

Completed

informCLL™: A Disease Registry for Patients With Chronic Lymphocytic Leukemia (informCLL)

Chronic Lymphocytic Leukemia (CLL)

United States
Duke University
Janssen, LP

Terminated

Functional Brain Imaging and Employment in First-Episode Psychotic Patients Treated With Risperdal

Schizophrenia

United States
Creighton University
Janssen, LP

Completed

Risperidone in the Treatment of PTSD in Women Survivors of Domestic Abuse and Rape Trauma

Post-Traumatic Stress Disorder

United States
Assistance Publique - Hôpitaux de Paris
Janssen, LP

Completed

Desensitization in Kidney Allograft Using Daratumumab (DARDAR)

Kidney Transplant Rejection | Antibody-mediated Rejection | Allosensitization

France
Assistance Publique - Hôpitaux de Paris
Janssen, LP

Recruiting

Initial Dual Oral Combination Therapy Versus Standard-of-care Initial Oral Monotherapy Prior to Balloon Pulmonary Angioplasty in Patients With Inoperable Chronic Thromboembolic Pulmonary Hypertension (IMPACT-CTEPH)

Chronic Disease | Inoperable Disease | Thromboembolic Pulmonary Hypertension

France
Imbrium Therapeutics
Purdue Pharma LP

Recruiting

Study of V117957 in Interstitial Cystitis/Bladder Pain Syndrome

Interstitial Cystitis/Bladder Pain Syndrome

United States

3

Subscribe